Opportunity Information: Apply for CDC RFA PS12 1203
Apply for CDC RFA PS12 1203
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Viral Hepatitis Surveillance" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.270 Adult Viral Hepatitis Prevention and Control.
- This funding opportunity was created on Sep 28, 2011 and posted on Sep 15, 2011.
- Applicants must submit their applications by Nov 1, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,100,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,200,000.00 in funding.
- The number of recipients for this funding is limited to 9 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Competition is limited to the nine health departments (California, Colorado, Connecticut, Georgia, Minnesota, New Mexico, New York, Oregon, Tennessee) currently funded for viral hepatitis surveillance under Funding Opportunity Announcement (FOA) CI05 026, Emerging Infectious Program. These sites are the only sources (within their jurisdictions) responsible for administering and enforcing laws, rules, or regulations pertaining to collecting and reporting of viral hepatitis surveillance data.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Viral Hepatitis Surveillance grant opportunity (Funding Opportunity Number CDC RFA PS12-1203) is a CDC cooperative agreement designed to strengthen active, enhanced public health surveillance for viral hepatitis. The core purpose is to monitor and better quantify the burden of both acute and chronic viral hepatitis by supporting standardized surveillance for acute hepatitis A, acute hepatitis B, acute hepatitis C, and chronic hepatitis B and C. In practice, this type of funding is meant to help health departments find cases more reliably, verify them, collect higher-quality epidemiologic and laboratory information, and report consistent data that can be used to track trends, detect outbreaks, and guide prevention and control efforts.
The opportunity is framed around the Healthy People 2020 Immunization and Infectious Diseases objectives, emphasizing measurable progress in reducing hepatitis transmission and improving awareness and prevention. Specifically, it aligns with goals to reduce or maintain elimination of new hepatitis B cases among children and adolescents ages 2 to 18 (IID 1.3), increase hepatitis B vaccination coverage among high-risk populations (IID 15), reduce hepatitis B infections among adults age 19 and older (IID 25.1), and reduce hepatitis B infections in higher-risk groups such as people who inject drugs (IID 25.2) and men who have sex with men (IID 25.3). It also supports broader hepatitis C priorities, including reducing new hepatitis C infections (IID 26) and increasing the proportion of people who are aware they have hepatitis C infection (IID 27). Taken together, the intent is to ensure surveillance systems are robust enough to measure prevention impact, identify populations most affected, and inform targeted vaccination, testing, and linkage-to-care strategies.
Administratively, this was a discretionary funding opportunity offered by the Centers for Disease Control and Prevention under the health activity category, using a cooperative agreement mechanism, which generally implies substantial CDC involvement in technical guidance, performance expectations, and program coordination. The CFDA number listed is 93.270 (Adult Viral Hepatitis Prevention and Control). The opportunity projected nine awards with an estimated total funding amount of $3.1 million, with individual award amounts ranging from a floor of $35,000 up to a ceiling of $1.2 million. No cost sharing or matching was required.
Eligibility was restricted and highly specific: competition was limited to the nine health departments already funded for viral hepatitis surveillance under the earlier FOA CI05-026 (Emerging Infections Program). The eligible jurisdictions were California, Colorado, Connecticut, Georgia, Minnesota, New Mexico, New York, Oregon, and Tennessee. The rationale provided is that these sites are the only entities in their jurisdictions responsible for administering and enforcing the laws and regulations tied to collecting and reporting viral hepatitis surveillance data, making them uniquely positioned to carry out the required public health surveillance functions.
Key dates show this was a time-limited solicitation posted on September 15, 2011, with an original and current closing date of November 1, 2011, and an archive date of December 1, 2011. Applicants needing help accessing the full announcement were directed to the CDC Procurement and Grants Office Technical Information Management Section (TIMS) at 770-488-2700, with instructions indicating the full announcement was available through the posting page (not via an active external link in the text provided).
Frequently Asked Questions (FAQ) - Viral Hepatitis Surveillance (CDC RFA PS12-1203)
What is the Viral Hepatitis Surveillance grant opportunity (CDC RFA PS12-1203)?
This opportunity is a CDC discretionary cooperative agreement intended to strengthen active, enhanced public health surveillance for viral hepatitis. The focus is on improving how health departments find, verify, document, and report hepatitis cases so the resulting data can be used to monitor trends, detect outbreaks, and guide prevention and control activities.
What is the main purpose of this funding?
The core purpose is to monitor and better quantify the burden of both acute and chronic viral hepatitis by supporting standardized surveillance. In practical terms, it supports more reliable case finding, case verification, higher-quality epidemiologic and laboratory information, and consistent reporting that can be used for public health action.
Which hepatitis conditions are specifically included in the standardized surveillance work?
The opportunity supports standardized surveillance for:
- Acute hepatitis A
- Acute hepatitis B
- Acute hepatitis C
- Chronic hepatitis B
- Chronic hepatitis C
How would this funding improve surveillance in practice?
Based on the description provided, the funding is meant to help health departments:
- Find cases more reliably (active, enhanced case identification)
- Verify cases (confirming that reported events meet surveillance definitions)
- Collect higher-quality epidemiologic information
- Collect higher-quality laboratory information
- Report standardized, consistent data usable for trend analysis and outbreak detection
- Support prevention and control efforts by informing targeted strategies
What public health goals does this opportunity align with?
The opportunity is framed around Healthy People 2020 Immunization and Infectious Diseases objectives, with an emphasis on measurable progress in reducing hepatitis transmission and improving awareness and prevention.
Which Healthy People 2020 objectives related to hepatitis B are referenced?
The opportunity references objectives that include:
- Reducing or maintaining elimination of new hepatitis B cases among children and adolescents ages 2 to 18 (IID 1.3)
- Increasing hepatitis B vaccination coverage among high-risk populations (IID 15)
- Reducing hepatitis B infections among adults age 19 and older (IID 25.1)
- Reducing hepatitis B infections among higher-risk groups such as people who inject drugs (IID 25.2) and men who have sex with men (IID 25.3)
Which Healthy People 2020 objectives related to hepatitis C are referenced?
The opportunity supports broader hepatitis C priorities, including:
- Reducing new hepatitis C infections (IID 26)
- Increasing the proportion of people who are aware they have hepatitis C infection (IID 27)
Why does CDC emphasize surveillance as part of prevention and control?
The description indicates the intent is to ensure surveillance systems are robust enough to measure prevention impact, identify populations most affected, and inform targeted vaccination, testing, and linkage-to-care strategies.
What type of funding mechanism is this?
This is a CDC cooperative agreement. The information provided notes that a cooperative agreement generally implies substantial CDC involvement in technical guidance, performance expectations, and program coordination.
Which agency offered this opportunity?
The opportunity was offered by the Centers for Disease Control and Prevention (CDC) under the health activity category.
What is the CFDA number for this program?
The CFDA number listed is 93.270, titled Adult Viral Hepatitis Prevention and Control.
How many awards were expected, and what was the estimated total funding?
The opportunity projected nine awards with an estimated total funding amount of $3.1 million.
What was the range of individual award amounts?
Individual award amounts ranged from a floor of $35,000 to a ceiling of $1.2 million.
Was cost sharing or matching required?
No. The information provided states that no cost sharing or matching was required.
Who was eligible to apply?
Eligibility was restricted to the nine health departments already funded for viral hepatitis surveillance under the earlier FOA CI05-026 (Emerging Infections Program). Competition was limited to those existing sites.
Which jurisdictions were eligible under this restricted competition?
The eligible jurisdictions listed were:
- California
- Colorado
- Connecticut
- Georgia
- Minnesota
- New Mexico
- New York
- Oregon
- Tennessee
Why was eligibility limited to those nine health departments?
The rationale given is that these sites are the only entities in their jurisdictions responsible for administering and enforcing the laws and regulations tied to collecting and reporting viral hepatitis surveillance data. This makes them uniquely positioned to carry out the required public health surveillance functions described in the opportunity.
When was the opportunity posted?
The posting date provided is September 15, 2011.
What was the application closing date?
The original and current closing date listed is November 1, 2011.
When was the opportunity archived?
The archive date listed is December 1, 2011.
Who should be contacted for help accessing the full announcement?
Applicants needing help accessing the full announcement were directed to the CDC Procurement and Grants Office Technical Information Management Section (TIMS) at 770-488-2700.
Where was the full announcement available?
The information provided indicates the full announcement was available through the posting page. The text provided does not include an active external link, but it notes the announcement could be accessed via the posting page referenced in the notice.
What is the Funding Opportunity Number (FON) for this solicitation?
The Funding Opportunity Number is CDC RFA PS12-1203.
How is this opportunity connected to outbreak detection and trend monitoring?
The description states that strengthening standardized surveillance and improving data quality supports consistent reporting that can be used to track trends and detect outbreaks, which in turn helps guide prevention and control efforts.
Does the opportunity focus only on acute hepatitis?
No. The opportunity explicitly includes both acute and chronic viral hepatitis, covering acute hepatitis A, acute hepatitis B, acute hepatitis C, and chronic hepatitis B and C.
Is this opportunity still open?
No. Based on the dates provided, the closing date was November 1, 2011, and the archive date was December 1, 2011.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Applied Research and Technology Development Award (ARATDA) Psychological Health, Polytrauma, and Operational Health
Previous opportunity: National Park Service Front End Development for Biodiversity Database
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS12 1203
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS12 1203) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDCR Clinical Trial or Biomarker Clinical Evaluation Study Planning Grant (R34) Apply for PAR 11 338 Funding Number: PAR 11 338 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Clinical Trial Implementation or Biomarker Clinical Evaluation Study Cooperative Agreement (U01) Apply for PAR 11 339 Funding Number: PAR 11 339 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanisms Explaining Differences in Depressive and Anxiety Disorders Across Racial/Ethnic Groups (R01) Apply for RFA MH 12 090 Funding Number: RFA MH 12 090 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AIDS Education and Training Centers (AETC) National Evaluation Center (NEC) Apply for HRSA 12 071 Funding Number: HRSA 12 071 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Neurological Emergencies Treatment Trials (NETT) Network Clinical Site Hubs for year 2011 (U10) Apply for PAR 11 342 Funding Number: PAR 11 342 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIH Directors Transformative Research Awards (R01) Apply for RFA RM 11 006 Funding Number: RFA RM 11 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NeuroNEXT Clinical Trials (U01) Apply for PAR 11 343 Funding Number: PAR 11 343 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NeuroNEXT Small Business Innovation in Clinical Trials (U44) Apply for PAR 11 345 Funding Number: PAR 11 345 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NeuroNEXT Infrastructure Resource Access (X01) Apply for PAR 11 344 Funding Number: PAR 11 344 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Health Care Services Outreach Grant Program Apply for HRSA 12 083 Funding Number: HRSA 12 083 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NINDS SBIR Technology Transfer (SBIR TT R43/R44) Apply for PA 11 347 Funding Number: PA 11 347 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| NIDCR Limited Competition Renewals of Existing Cooperative Agreement Awards, Prospective Studies on Craniofacial Pain and Dysfunction RFA DE 05 007 (U01) Apply for PAR 11 348 Funding Number: PAR 11 348 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Hubs for International Research on Mental Health (U19) Apply for RFA MH 12 110 Funding Number: RFA MH 12 110 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Tuskegee University Apology Commemoration Activities Apply for CDC RFA PS12 1202 Funding Number: CDC RFA PS12 1202 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $180,000 |
| FY12 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Wisconsin) Apply for PA FPH 12 012 Funding Number: PA FPH 12 012 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $3,671,742 |
| FY12 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (West Virginia) Apply for PA FPH 12 013 Funding Number: PA FPH 12 013 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,405,407 |
| FY12 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Pennsylvania, Western, Northeastern, and Central) Apply for PA FPH 12 014 Funding Number: PA FPH 12 014 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $3,941,586 |
| FY12 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Georgia) Apply for PA FPH 12 015 Funding Number: PA FPH 12 015 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $8,229,100 |
| FY12 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Kentucky) Apply for PA FPH 12 016 Funding Number: PA FPH 12 016 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $5,621,689 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 13 001 Funding Number: RFA GM 13 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS12 1203", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.